Johnson & Johnson reported a 7.4 percent fall in quarterly sales as the impact of a strong dollar more than offset higher sales of its older drugs such as Invega line of products for schizophrenia and ADHD treatment Concerta. Alex Gorsky, CEO of Johnson & Johnson, listens as he is introduced to speak at the Boston College Chief Executives Club of Boston luncheon in Boston, Massachusetts September 11, 2015.